VIROMETIX

Virometix AG is a privately held Swiss biotechnology company whose purpose is the discovery and development of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer. The company is a spinout from the department of organic chemistry at the University of Zurich which provided the expertise in structural biology and synthetic chemistry that laid the foundation for our synthetic nanoparticle platform technology. Our present focus is the generation of a novel, peptide antigen-based vaccine with the potential to provide serotype-independent protective immunity against infection caused by Streptococcus pneumoniae... Virometix AG is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer... At Virometix, we believe that fully synthetic vaccines that generate selective immune responses against synthetic antigens mimicking critically important native epitopes on..

Also known as: Virometix AG

Primary location: Schlieren Switzerland